Literature DB >> 26137043

Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cells.

Li Shan Ma1, Q I Yan2, Yongfang Huang2, Wenxia Zhao2, Y U Zhu2.   

Abstract

The aim of the current study was to investigate the suppressive effects of pSilencer T7-human epidermal growth factor receptor 2 (HER2)-short hairpin RNA (shRNA) recombinant plasmids on human SKOV3 ovarian cancer cell growth and sensitivity to carboplatin (CBP). Three different pairs of shRNAs (shRNAa, shRNAb and shRNAc), targeting the HER2 gene, were selected and transfected into human SKOV3 cells, respectively. The expression levels of HER2 were then detected by immunohistochemical (IHC), semi-quantitative reverse transcription-polymerase chain reaction and western blot analyses. In addition, cell cycle and cell growth were investigated using cell counting kit-8 (CCK-8). The results of the IHC and western blot analyses revealed that shRNAb significantly inhibited HER2 protein expression in SKOV3 cells. shRNAb exhibited an improved effect on HER2 expression compared with shRNAa (P<0.01), while shRNAc did not affect HER2 expression. Nontransfected and nonspecific shRNA groups were used as the negative controls. Knockdown of HER2 expression by shRNA was initiated at 24 h following transfection, achieving an optimum effect at 48 h and lasting for at least 72 h after the treatment. The CCK-8 cell growth assay indicated that the knockdown of HER2 expression in the SKOV3 cell line resulted in significant growth suppression and cell cycle arrest. In addition, inhibition of HER2 significantly increased SKOV3 cell sensitivity to CBP treatment. In conclusion, pSilencer T7-HER2-shRNA significantly inhibited HER2 expression in human ovarian cancer cells in vitro and induced chemotherapeutic sensitivity to CBP.

Entities:  

Keywords:  SKOV3 cells; chemosensitivity; human epidermal growth factor receptor 2; ovarian cancer; short hairpin RNA

Year:  2015        PMID: 26137043      PMCID: PMC4467329          DOI: 10.3892/ol.2015.3033

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  37 in total

1.  Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  N Colombo; M Peiretti; G Parma; M Lapresa; R Mancari; S Carinelli; C Sessa; M Castiglione
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

Review 2.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

3.  HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer.

Authors:  Wan-Ru Chao; Ming-Yung Lee; Wea-Long Lin; Chi-Kuan Chen; Jau-Chen Lin; Chiew-Loon Koo; Gwo-Tarng Sheu; Chih-Ping Han
Journal:  Hum Pathol       Date:  2013-12-12       Impact factor: 3.466

Review 4.  The role of HER2 in cancer therapy and targeted drug delivery.

Authors:  Wanyi Tai; Rubi Mahato; Kun Cheng
Journal:  J Control Release       Date:  2010-04-10       Impact factor: 9.776

5.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

6.  HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice.

Authors:  Fabio Corsi; Luisa Fiandra; Clara De Palma; Miriam Colombo; Serena Mazzucchelli; Paolo Verderio; Raffaele Allevi; Antonella Tosoni; Manuela Nebuloni; Emilio Clementi; Davide Prosperi
Journal:  ACS Nano       Date:  2011-08-01       Impact factor: 15.881

7.  HER-2/neu oncogene protein and prognosis in breast cancer.

Authors:  A K Tandon; G M Clark; G C Chamness; A Ullrich; W L McGuire
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

Review 8.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

9.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

10.  c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.

Authors:  Mario Campone; Bélinda Noël; Cécile Couriaud; Morgan Grau; Yannis Guillemin; Fabien Gautier; Wilfried Gouraud; Catherine Charbonnel; Loïc Campion; Pascal Jézéquel; Frédérique Braun; Benjamin Barré; Olivier Coqueret; Sophie Barillé-Nion; Philippe Juin
Journal:  Mol Cancer       Date:  2011-09-07       Impact factor: 27.401

View more
  2 in total

1.  Differences in Zbtb7a expression cause heterogeneous changes in human nasopharyngeal carcinoma CNE3 sublines.

Authors:  Fei Liu; Jiao Lan; Wei Jiao; Xianglan Mo; Yongta Huang; Huilan Ye; Ruiping Xiao; Yongli Wang; Mingzheng Mo; Liwei Shi
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

2.  MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2).

Authors:  Na Li; Mei Han; Ning Zhou; Yong Tang; Xu-Shan Tang
Journal:  Med Sci Monit       Date:  2018-08-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.